Champions Oncology (CSBR) Capital Leases (2018)

Champions Oncology (CSBR) recorded quarterly Capital Leases of $95000.0 in Q4 2018, down 35.81% quarter-over-quarter from $148000.0 in Q3 2018.

Champions Oncology (CSBR) Capital Leases (2018) Analysis & Trends

Champions Oncology's Capital Leases history runs 1 years deep, the most recent figure standing at $95000.0 for Q4 2018.

In Q4 2018, Capital Leases changed N/A year-over-year to $95000.0; the TTM figure through Oct 2018 stood at $95000.0 (changed N/A YoY), while the FY2018 annual figure was $17000.0, changed N/A from the prior year.
Capital Leases was $95000.0 for Q4 2018 at Champions Oncology, down from $148000.0 in the prior quarter.
In the past five years, Capital Leases ranged from a high of $148000.0 in Q3 2018 to a low of $17000.0 in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Champions Oncology	78.46 Mn	71.46 Mn	13.89 Mn

Download Data